Clopidogrel side effects: what 197,000 FDA adverse event reports show
Drug class
Not stated in label
Who reports
197,000 reports · 81% serious · 21,779 with death outcome · 44% female
Used for
Clopidogrel tablets USP are a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome • For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel tablets USP have been .
What it is
Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer).
Boxed warning
DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [ see Warnings and Precautions ( 5.1 ) ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,180 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vascular stent thrombosis | 642 | 48.9 44.5–53.7ROR 49.1 · calibrated p 2e-5 ✓ | 33.6 EB05 31.4 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=642 | not reported in cached trials |
| Stent occlusion | 167 | 47.6 39.6–57.2ROR 47.6 · calibrated p 2e-5 ✓ | 32.9 EB05 28.9 · IC025 +4.7 3/3 methods agree | Not in label — unassessed | serious n=157 · 100% clinician | not reported in cached trials |
| Coronary artery restenosis | 173 | 42.7 35.8–51.0ROR 42.8 · calibrated p 4e-5 ✓ | 30.5 EB05 26.9 · IC025 +4.6 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=171 · ♀ 0% (drug 44%) · 100% clinician | not reported in cached trials |
| Spinal epidural haematoma | 123 | 29.5 24.1–36.0ROR 29.5 · calibrated p 3e-4 ✓ | 23.1 EB05 19.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=123 · ♀ 100% (drug 44%) · 100% clinician | not reported in cached trials |
| Coronary arterial stent insertion | 936 | 24.0 22.3–25.8ROR 24.1 · calibrated p 8e-4 ✓ | 19.7 EB05 18.6 · IC025 +4.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=926 | not reported in cached trials |
| Multiple injuries | 1,130 | 22.8 21.4–24.3ROR 22.9 · calibrated p 0.001 ✓ | 18.9 EB05 17.9 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=1,129 · 85% consumer | not reported in cached trials |
| Vascular pseudoaneurysm | 291 | 21.1 18.6–24.0ROR 21.2 · calibrated p 0.002 ✓ | 17.7 EB05 16.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=286 | NCT00335452: 9/6,253 (0.1%) on Clopidogrel (serious AE) |
| Thrombosis in device | 544 | 20.8 18.9–22.8ROR 20.8 · calibrated p 0.002 ✓ | 17.5 EB05 16.3 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=541 | not reported in cached trials |
| Labelled drug-drug interaction medication error | 1,322 | 18.4 17.3–19.5ROR 18.5 · calibrated p 0.003 ✓ | 15.8 EB05 15.1 · IC025 +3.9 3/3 methods agree | Reporting / coding artifact | serious PRR 13.1 | not reported in cached trials |
| Ulcer haemorrhage | 998 | 18.3 17.1–19.5ROR 18.4 · calibrated p 0.003 ✓ | 15.7 EB05 14.9 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=992 · 90% consumer | NCT00335452: 3/6,253 (0.0%) on Clopidogrel (serious AE) |
| Chronic kidney disease-mineral and bone disorder | 150 | 17.1 14.4–20.3ROR 17.1 · calibrated p 0.004 ✓ | 14.8 EB05 12.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=150 | not reported in cached trials |
| Coronary artery stenosis | 700 | 17.0 15.7–18.4ROR 17.1 · calibrated p 0.004 ✓ | 14.8 EB05 13.9 · IC025 +3.7 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=697 | not reported in cached trials |
| Haemorrhagic arteriovenous malformation | 127 | 16.4 13.6–19.8ROR 16.4 · calibrated p 0.005 ✓ | 14.2 EB05 12.3 · IC025 +3.5 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=127 · ♀ 0% (drug 44%) · 100% consumer | not reported in cached trials |
| Hyperparathyroidism secondary | 336 | 16.2 14.4–18.1ROR 16.2 · calibrated p 0.005 ✓ | 14.1 EB05 12.9 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=336 | not reported in cached trials |
| Thrombotic thrombocytopenic purpura | 456 | 15.7 14.2–17.3ROR 15.7 · calibrated p 0.006 ✓ | 13.7 EB05 12.7 · IC025 +3.6 3/3 methods agree | Labeled — boxed warning exact term | serious n=456 | not reported in cached trials |
| Coronary artery thrombosis | 258 | 15.4 13.5–17.6ROR 15.4 · calibrated p 0.006 ✓ | 13.5 EB05 12.2 · IC025 +3.5 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=255 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Intermittent claudication | 200 | 15.1 13.1–17.6ROR 15.2 · calibrated p 0.007 ✓ | 13.3 EB05 11.8 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=191 | not reported in cached trials |
| Angina unstable | 820 | 15.1 14.0–16.2ROR 15.1 · calibrated p 0.007 ✓ | 13.3 EB05 12.5 · IC025 +3.6 3/3 methods agree | Likely indication confounding term in indications | serious n=816 | not reported in cached trials |
| Nephrogenic anaemia | 576 | 14.8 13.6–16.2ROR 14.9 · calibrated p 0.007 ✓ | 13.1 EB05 12.2 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=576 | NCT00335452: 2/6,253 (0.0%) on Clopidogrel (serious AE) |
| Angioplasty | 184 | 14.8 12.7–17.3ROR 14.8 · calibrated p 0.008 ✓ | 13.0 EB05 11.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=182 | not reported in cached trials |
| Coronary artery occlusion | 1,659 | 14.4 13.7–15.2ROR 14.6 · calibrated p 0.008 ✓ | 12.8 EB05 12.3 · IC025 +3.6 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious PRR 9.1 | not reported in cached trials |
| Carotid artery stenosis | 421 | 14.4 13.0–15.9ROR 14.4 · calibrated p 0.008 ✓ | 12.7 EB05 11.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=419 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Stent placement | 938 | 13.9 13.0–14.9ROR 14.0 · calibrated p 0.009 ✓ | 12.4 EB05 11.7 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious PRR 8.8 | not reported in cached trials |
| Arterial haemorrhage | 131 | 13.6 11.3–16.3ROR 13.6 · calibrated p 0.011 ✓ | 12.0 EB05 10.4 · IC025 +3.3 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=131 · ♀ 100% (drug 44%) · 100% clinician | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Ischaemic cardiomyopathy | 350 | 13.4 12.0–15.0ROR 13.5 · calibrated p 0.011 ✓ | 12.0 EB05 11.0 · IC025 +3.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=348 | not reported in cached trials |
| Carotid arteriosclerosis | 115 | 13.4 11.0–16.2ROR 13.4 · calibrated p 0.012 ✓ | 11.8 EB05 10.1 · IC025 +3.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=114 · ♀ 0% (drug 44%) · 100% clinician | not reported in cached trials |
| Diverticulum intestinal haemorrhagic | 249 | 13.0 11.4–14.9ROR 13.1 · calibrated p 0.013 ✓ | 11.6 EB05 10.5 · IC025 +3.3 3/3 methods agree | Labeled (related wording) related wording | serious n=247 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Extradural haematoma | 141 | 12.5 10.5–14.9ROR 12.5 · calibrated p 0.015 ✓ | 11.2 EB05 9.7 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=140 · 100% clinician | not reported in cached trials |
| Retroperitoneal haematoma | 229 | 12.3 10.7–14.1ROR 12.3 · calibrated p 0.016 ✓ | 11.0 EB05 9.9 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | serious n=227 · 100% clinician | NCT00335452: 2/6,253 (0.0%) on Clopidogrel (serious AE) |
| Acute myocardial infarction | 3,083 | 12.3 11.8–12.7ROR 12.4 · calibrated p 0.015 ✓ | 11.1 EB05 10.8 · IC025 +3.4 3/3 methods agree | Likely indication confounding term in indications | serious PRR 7.8 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Retroperitoneal haemorrhage | 253 | 12.0 10.6–13.7ROR 12.1 · calibrated p 0.017 ✓ | 10.8 EB05 9.7 · IC025 +3.2 3/3 methods agree | Labeled adverse reaction exact term | serious n=253 | NCT00335452: 8/6,253 (0.1%) on Clopidogrel (serious AE) |
| Coronary artery disease | 3,080 | 11.9 11.4–12.3ROR 12.0 · calibrated p 0.017 ✓ | 10.7 EB05 10.4 · IC025 +3.4 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious PRR 7.7 | not reported in cached trials |
| Peripheral arterial occlusive disease | 413 | 11.8 10.7–13.1ROR 11.8 · calibrated p 0.018 ✓ | 10.7 EB05 9.8 · IC025 +3.2 3/3 methods agree | Likely indication confounding shares a disease stem with the indications wording | serious n=407 | NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE) |
| Gastrointestinal haemorrhage | 8,285 | 11.5 11.3–11.8ROR 12.0 · calibrated p 0.017 ✓ | 10.5 EB05 10.3 · IC025 +3.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 6.9 · serious PRR 7.5 | NCT00335452: 15/6,253 (0.2%) on Clopidogrel (serious AE) |
| Blood loss anaemia | 216 | 11.3 9.8–13.0ROR 11.3 · calibrated p 0.021 ✓ | 10.2 EB05 9.1 · IC025 +3.1 3/3 methods agree | Labeled (related wording) related wording | serious n=215 · 100% clinician | not reported in cached trials |
| Mallory-weiss syndrome | 122 | 11.2 9.3–13.5ROR 11.2 · calibrated p 0.023 ✓ | 10.1 EB05 8.6 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=122 · ♀ 0% (drug 44%) · 100% clinician | not reported in cached trials |
| Upper gastrointestinal haemorrhage | 1,605 | 11.1 10.5–11.7ROR 11.2 · calibrated p 0.022 ✓ | 10.1 EB05 9.7 · IC025 +3.3 3/3 methods agree | Labeled (related wording) related wording | serious PRR 7.2 | NCT00335452: 15/6,253 (0.2%) on Clopidogrel (serious AE) |
| Acute coronary syndrome | 774 | 10.8 10.0–11.6ROR 10.8 · calibrated p 0.025 ✓ | 9.8 EB05 9.3 · IC025 +3.2 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 7.0 | NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE) |
| Peripheral artery occlusion | 129 | 10.7 8.9–12.8ROR 10.7 · calibrated p 0.026 ✓ | 9.7 EB05 8.3 · IC025 +3.0 3/3 methods agree | Not in label — unassessed | serious n=127 · 100% consumer | not reported in cached trials |
| Melaena (black stool) | 1,995 | 10.5 10.0–11.0ROR 10.6 · calibrated p 0.026 ✓ | 9.6 EB05 9.3 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | age-adj. PRR 6.3 · serious PRR 6.9 | NCT00335452: 1/6,312 (0.0%) on Clopidogrel (serious AE) |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Gi bleeding | 14,245 | 8.98.8–9.1 | signal |
| Myocardial infarction | 12,470 | 6.96.7–7.0 | signal |
| Stroke | 10,746 | 4.84.7–4.8 | signal |
| Heart failure | 5,873 | 3.63.5–3.7 | signal |
| Anaemia | 8,892 | 3.23.2–3.3 | signal |
| Rhabdomyolysis / myopathy | 2,318 | 3.13.0–3.2 | signal |
| Kidney injury | 11,855 | 2.82.8–2.9 | signal |
| Arrhythmia / qt | 4,824 | 2.72.6–2.8 | signal |
| Hyponatraemia | 1,990 | 2.72.6–2.8 | signal |
| Hypoglycaemia | 2,040 | 2.32.2–2.4 | signal |
| Fall / fracture | 7,114 | 2.02.0–2.1 | raised |
| Hyperglycaemia / diabetes | 5,069 | 1.61.5–1.6 | raised |
| Venous thromboembolism | 3,112 | 1.51.5–1.6 | raised |
| Thrombocytopenia | 3,023 | 1.51.4–1.5 | raised |
| Interstitial lung disease | 1,274 | 1.41.3–1.5 | raised |
| Serious infection | 9,536 | 1.31.3–1.3 | raised |
Trial evidence (ClinicalTrials.gov)
✓ Trial adverse-event data found on ClinicalTrials.gov
Largest completed trials with posted results that list Clopidogrel as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (15 of 40 signal terms matched).
- NCT00335452 — Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for Interventi (N=25086, PHASE3; 408 AE terms posted; arms: Clopidogrel 300/75/75 mg + ASA Low Dose; Clopidogrel 300/75/75 mg + ASA High Dose; Clopidogrel 600/150/75 mg + ASA Low Dose; Clopidogrel 600/150/75 mg + ASA High Dos)
Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Dyspnoea (shortness of breath) | 10,179 | 1.9 1.9–2.0ROR 2.0 · calibrated p 0.935 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 1.6 | NCT00335452: 2/6,312 (0.0%) on Clopidogrel (serious AE) |
| Myocardial infarction (heart attack) | 9,531 | 6.0 5.9–6.2ROR 6.3 · calibrated p 0.132 | 5.8 EB05 5.7 · IC025 +2.5 3/3 methods agree | Likely indication confounding term in indications | age-adj. PRR 5.5 · serious PRR 4.1 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Fatigue (tiredness) | 8,717 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.444 | 1.2 EB05 1.2 · IC025 +0.2 | Not in label — unassessed | age-adj. PRR 1.0 · serious PRR 1.2 | NCT00335452: 1/6,312 (0.0%) on Clopidogrel (serious AE) |
| Gastrointestinal haemorrhage | 8,285 | 11.5 11.3–11.8ROR 12.0 · calibrated p 0.017 ✓ | 10.5 EB05 10.3 · IC025 +3.4 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 6.9 · serious PRR 7.5 | NCT00335452: 15/6,253 (0.2%) on Clopidogrel (serious AE) |
| Nausea | 8,081 | 1.1 1.1–1.1ROR 1.1 · calibrated p 0.369 | 1.1 EB05 1.1 · IC025 +0.1 | Not in label — unassessed | age-adj. PRR 1.0 · serious PRR 1.1 | NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE) |
| Dizziness | 7,884 | 1.7 1.7–1.7ROR 1.7 · calibrated p 0.785 | 1.7 EB05 1.7 · IC025 +0.7 | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.6 | NCT00335452: 1/6,267 (0.0%) on Clopidogrel (serious AE) |
| Diarrhoea (diarrhea) | 7,600 | 1.3 1.2–1.3ROR 1.3 · calibrated p 0.488 | 1.3 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.0 · serious PRR 1.2 | NCT00335452: 1/6,253 (0.0%) on Clopidogrel (serious AE) |
| Drug ineffective (drug did not work) | 7,405 | 0.6 0.6–0.6ROR 0.6 · calibrated p 0.077 | 0.6 EB05 0.6 · IC025 -0.8 PRR-only: not supported by EBGM or IC | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 0.8 | not reported in cached trials |
| Asthenia (weakness) | 6,859 | 2.0 1.9–2.0ROR 2.0 · calibrated p 0.941 | 1.9 EB05 1.9 · IC025 +0.9 | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 1.6 | not reported in cached trials |
| Fall | 6,697 | 2.2 2.1–2.2ROR 2.2 · calibrated p 0.947 | 2.1 EB05 2.1 · IC025 +1.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.4 · serious PRR 1.7 | NCT00335452: 1/6,253 (0.0%) on Clopidogrel (serious AE) |
| Cerebrovascular accident (stroke) | 6,523 | 4.2 4.1–4.3ROR 4.3 · calibrated p 0.323 | 4.1 EB05 4.0 · IC025 +2.0 3/3 methods agree | Labeled — boxed warning synonym match | age-adj. PRR 3.4 · serious PRR 2.9 | not reported in cached trials |
| Death | 6,180 | 0.8 0.7–0.8ROR 0.8 · calibrated p 0.158 | 0.8 EB05 0.7 · IC025 -0.4 PRR-only: not supported by EBGM or IC | Outcome field, not a reaction | age-adj. PRR 0.5 · serious PRR 0.5 | not reported in cached trials |
| Anaemia (low red blood cells) | 6,155 | 3.5 3.4–3.6ROR 3.6 · calibrated p 0.462 | 3.4 EB05 3.4 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.8 · serious PRR 2.6 | NCT00335452: 2/6,312 (0.0%) on Clopidogrel (serious AE) |
| Headache | 5,605 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.275 | 1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Labeled adverse reaction exact term | age-adj. PRR 1.0 · serious PRR 1.0 | NCT00335452: 1/6,254 (0.0%) on Clopidogrel (serious AE) |
| Pain | 5,517 | 1.0 0.9–1.0ROR 1.0 · calibrated p 0.276 | 1.0 EB05 0.9 · IC025 -0.1 PRR-only: not supported by EBGM or IC | Not in label — unassessed | age-adj. PRR 1.1 · serious PRR 0.9 | NCT00335452: 3/6,253 (0.0%) on Clopidogrel (serious AE) |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vascular stent thrombosis — n=642, PRR 48.9
- Stent occlusion — n=167, PRR 47.6
- Spinal epidural haematoma — n=123, PRR 29.5
- Multiple injuries — n=1,130, PRR 22.8
- Vascular pseudoaneurysm — n=291, PRR 21.1 (also seen in trial arm)
- Thrombosis in device — n=544, PRR 20.8
- Chronic kidney disease-mineral and bone disorder — n=150, PRR 17.1
- Hyperparathyroidism secondary — n=336, PRR 16.2
- Intermittent claudication — n=200, PRR 15.1
- Nephrogenic anaemia — n=576, PRR 14.8 (also seen in trial arm)
✓ A hand-written Bradford Hill causality assessment exists for this drug: Clopidogrel ↔ Gastrointestinal haemorrhage.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Clopidogrel?
In FDA FAERS, the most frequently co-reported reaction terms for Clopidogrel are dyspnoea, myocardial infarction, fatigue, gastrointestinal haemorrhage, nausea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Clopidogrel have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS The effectiveness of clopidogrel is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [ see Warnings and Precautions ( 5.1 ) ].
Do FAERS signals prove that Clopidogrel causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 25ed3120-7960-4e87-8422-de5c2026062c, effective 20210101; matched on
openfda.generic_name.exact:"CLOPIDOGREL" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 60606 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,220 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
CLOPIDOGREL, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.